BNUB0302
CD43(Bra7G), 0.2mg/mL
Eine Lieferung in diese Region ist nicht möglich.
- SKU:
- BNUB0302
- Zusätzliche Namen:
- Galactoglycoprotein, GALGP, GPL115, Leukocyte sialoglycoprotein, Leukosialin, LSN, Sialophorin, SPN
- Anwendung:
- Flow Cytometry, IHC-P, IF, IP
- Konzentration:
- 0.2 mg/ml
- Molekulargewicht:
- 95, 115, or 135 kDa
- Quelle:
- Animal
- Lagerbedingungen:
- 2-8[o]C, RT
- Hersteller:
- Biotium
- Host:
- Mouse
- Reaktivitäten:
- Bovine, Human, Mouse
- Buffer:
- PBS, 0.05% BSA, 0.05% azide|PBS, 0.05% BSA, 0.05% sodium azide
- Immunogen:
- Immature pluripotent human leukemia K562 cells
- Formulierung:
- PBS, 0.05% BSA, 0.05% azide
- Klon:
- Bra7G
- Uniprot:
- P16150
- Synonyme:
- CD43;galactoglycoprotein;GALGP;GPL115;leukocyte sialoglycoprotein;leukosialin;LSN;Sialophorin;sialophorin (gpL115, leukosialin, CD43)
- Weitere Details:
- This antibody recognizes a cell surface glycoprotein of 95/115/135 kDa (depending upon the extent of glycosylation), identified as CD43 (Workshop V). Epitope of MAb Bra7G is clearly different from that of MAb DF-T1, called b as opposed to a for DF-T1. 70-90% of T-cell lymphomas and from 22-37% of B-cell lymphomas express CD43. No reactivity has been observed with reactive B-cells. So a B-lineage population that co-expresses CD43 is highly likely to be a malignant lymphoma, especially a low-grade lymphoma, rather than a reactive B-cell population. When CD43 antibody is used in combination with anti-CD20, effective immunophenotyping of the lymphomas in formalin-fixed tissues can be obtained. Co-staining of a lymphoid infiltrate with anti-CD20 and anti-CD43 argues against a reactive process and favors a diagnosis of lymphoma. This antibody is available purified with BSA/azide at 200 ug/mL, or BSA/azide-free at 1 mg/mL.
- Versandbedingungen:
- Ambient